Prostaglandin-induced iris color darkening: An experimental model

Archives of Ophthalmology

Volumn 116, Issue 8, 1998, Pages 1065-1068

  Zhan, Gui Lin ^a   Toris, Carol B ^a   Camras, Carl B ^a,c   Wang, Yun Liang ^a   Bito, Laszlo Z ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Howard Hughes Medical Institute   (United States)

^c Pharmacia and Upjohn   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; LATANOPROST; MELANIN; PROSTAGLANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EYE COLOR; MELANOGENESIS; NEUROMODULATION; NONHUMAN; PIGMENT DISORDER; PRIORITY JOURNAL; RABBIT; SUPERIOR CERVICAL GANGLIONECTOMY; SYMPATHETIC INNERVATION; TOPICAL DRUG ADMINISTRATION;

EID: 0032454460     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.116.8.1065     Document Type: Article

References (24)

1. Camras CB. Prostaglandins and the treatment of the glaucomas. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St Louis, Mo: Mosby-Year Book Inc; 1996: 1449-1461.
2. Camras CB, for the US Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a 6-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
3. Camras CB, Alm A, Watson PG, Stjernschantz J, for the Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy: efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology. 1996;103:1916-1924.
4. Alm A, Stjernschantz J, for the Scandinavian Latanoprost Study Group. Effects on intraxular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology. 1995;102:1743-1752.
5. Watson PG, Stjernschantz J, for the Latanoprost Study Group. A 6-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.
6. Wistrand P, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(suppl 2):S129-S138.
7. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544-547.
8. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997;115:1206-1208.
9. Selén G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol. 1997;41(suppl 2):S125-S128.
10. Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res. 1992;5:357-361.
11. Eagle RC Jr. Iris pigmentation and pigmented lesions: an ultrastructural study. Trans Am Ophthalmol Soc. 1988;88:581-687.
12. Wilkerson CL, Syed NA, Fisher MR, Robinson NL, Wallow IHL, Albert DM. Melanocytes and iris color: light microscopic findings. Arch Ophthalmol. 1996;114: 437-442.
13. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color: electron microscopic findings. Arch Ophthalmol. 1996;114:443-447.
14. Calhoun FP. Causes of heterochromia iridis with special reference to paralysis of the cervical sympathetic. Am J Ophthalmol. 1919;2:255-269.
15. Calhoun FP. A consideration of the causes of heterochromia iridis, with special reference to a paralysis of the cervical sympathetic. Trans Am Ophthalmol Soc. 1919;16:277-312.
16. Laties AM. Ocular melanin and the adrenergic innervation to the eye. Trans Am Ophthalmol Soc. 1974;72:560-605.
17. Bito LZ. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol. 1997;41(suppl 2):S1-S14.
18. Diesenhouse MC, Palay DA, Newman NJ, To K, Albert DM. Acquired heterochromia with Horner syndrome in 2 adults. Ophthalmology. 1992;99:1815-1817.
19. Odin L, O'Donnell FE Jr. Adrenergic influence on iris stromal pigmentation: evidence for alpha-adrenergic receptors. Invest Ophthalmol Vis Sci. 1982;23:528-530.
20. Camras CB, Podos SM. The role of endogenous prostaglandin in clinically-used and investigational glaucoma therapy. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York, NY: Alan R Liss Inc; 1989;312:459-475.
21. Camras CB, Zhan G-L, Ohia S, Ohia E, Wang Y-L. The role of prostaglandins and neuropeptide Y in the reduction of intraocular pressure 1 day after sympathectomy in rabbits. Invest Ophthalmol Vis Sci. 1993;34(suppl):932.
22. Laties AM, Lerner AB. Iris colour and relationship of tyrosinase activity to adrenergic innervation. Nature. 1975;255:152-153.
23. Bito LZ, Matheny AP, Cruickshanks KJ, Nondahl DM, Carino OB. Eye color changes past childhood: the Louisville Twin Study. Arch Ophthalmol. 1997;115:659-663.
24. Dryja TP, Albert DM. Lack of adrenergic influence on the pigmentation of iris nevus cells. Arch Ophthalmol. 1980;98:1996.